<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zervas, K.</style></author><author><style face="normal" font="default" size="100%">Mihou, D.</style></author><author><style face="normal" font="default" size="100%">Katodritou, E.</style></author><author><style face="normal" font="default" size="100%">Pouli, A.</style></author><author><style face="normal" font="default" size="100%">Mitsouli, C.H.</style></author><author><style face="normal" font="default" size="100%">Anagnostopoulos, A.</style></author><author><style face="normal" font="default" size="100%">Delibasi, S.</style></author><author><style face="normal" font="default" size="100%">Kyrtsonis, M.C.</style></author><author><style face="normal" font="default" size="100%">Anagnostopoulos, N.</style></author><author><style face="normal" font="default" size="100%">Terpos, E.</style></author><author><style face="normal" font="default" size="100%">Zikos, P.</style></author><author><style face="normal" font="default" size="100%">Maniatis, A.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, M.A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: Results of a multicenter randomized trial of the Greek myeloma study group</style></title><secondary-title><style face="normal" font="default" size="100%">Annals of Oncology</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">multiple myeloma</style></keyword><keyword><style  face="normal" font="default" size="100%">Thalidomide</style></keyword><keyword><style  face="normal" font="default" size="100%">VAD-doxil</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2007</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2007</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-34548173936&amp;doi=10.1093%2fannonc%2fmdm178&amp;partnerID=40&amp;md5=94865afbd2903b5a1a6eb535c55b7d7d</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">18</style></volume><pages><style face="normal" font="default" size="100%">1369 - 1375</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Background: We have previously demonstrated that vincristine, liposomal doxorubicin and dexamethasone (VAD-doxil) is equally effective with VAD-bolus yielding objective response rates of 61% as first-line treatment in multiple myeloma (MM). In a phase II study, the addition of thalidomide to VAD-doxil (TVAD-doxil) proved feasible and increased response rate to 74%. The aim of the present multicenter prospective randomized clinical trial was to compare the efficacy and toxicity of VAD-doxil and TVAD-doxil in previously untreated MM patients. Patients and methods: We enrolled 232 newly diagnosed MM patients aged &amp;lt;75 years, 115 randomized to VAD-doxil (arm A) and 117 to TVAD-doxil (arm B). Patients in arm A received vincristine 2 mg i.v. and liposomal doxorubicin 40 mg/m2 i.v., on day 1 and dexamethasone 40 mg p.o. daily on days 1-4, 9-12 and 17-20 for the first cycle and on days 1-4 for the next three cycles. Patients in arm B received additionally thalidomide 200 mg p.o. daily, at bedtime. Treatment was administered every 28 days. Results: On an intention-to-treat basis, at least partial response was observed, in 62.6% and in 81.2% of patients randomized to arms A and B, respectively (P = 0.003). Progression-free survival (PFS) at 2 years was 44.8% in arm A and 58.9% in arm B (P = 0.013). Overall survival (OS) at 2 years was 64.6% and 77%, in arms A and B, respectively (P = 0.037). Considering overall toxicity, constipation, peripheral neuropathy, dizziness/somnolence, skin rash and edema were significantly higher in arm B compared with arm A (P &amp;lt; 0.01), but grade 3-4 toxicities were low and similar in both arms. Conclusions: The addition of thalidomide to VAD-doxil increases response and PFS rates and probably OS in previously untreated myeloma patients. The superiority of efficacy counterbalances the higher overall toxicity of TVAD-doxil. © 2007 European Society for Medical Oncology.</style></abstract><issue><style face="normal" font="default" size="100%">8</style></issue><notes><style face="normal" font="default" size="100%">Cited By :50Export Date: 21 February 2017</style></notes></record></records></xml>